Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VRC 320: Phase I Study of Zika Virus DNA Vaccine
NCT02996461Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2016
- Primary completion
- Sep 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VRC-ZKADNA090-00-VP in Zika virus infection (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety and tolerability of ZIKV DNA vaccine administered at 4mg IM by needle and syringe at 44 weeks and Safety and tolerability of ZIKV DNA vaccine administered at 4 mg IM by PharmaJet at 44 weeks. Started Dec 2016; status: completed.
02
Drugs
VRC-ZKADNA090-00-VP
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT02996461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02996461.